Healthcare Oversold Stocks: Halozyme Therapeutics (NASDAQ:HALO), Advaxis (NASDAQ:ADXS), PharmAthene (NYSEMKT:PIP), Prosensa Holding (NASDAQ:RNA)

On April 10, Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced that the U.S. Food and Drug Administration (:FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study (Study 202). The study is evaluating PEGPH20 as a first-line therapy for patients suffering from stage IV metastatic pancreatic cancer. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares after opening at $7.46 on last trade day and at the end of the day closed at $7.19. Company price to sales ratio in past twelve months was calculated as 16.33 and price to cash ratio as 12.52. Halozyme Therapeutics, Inc. (NASDAQ:HALO) showed a negative weekly performance of -12.95%.

On Apr 01, 2014, Advaxis, Inc. (NASDAQ:ADXS), announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company’s proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension. Advaxis, Inc. (NASDAQ:ADXS) shares fell -6.62% in last trading session and ended the day on $2.68. ADXS return on equity ratio is recorded as -400.00% and its return on assets is -154.60%. Advaxis, Inc. (NASDAQ:ADXS) yearly performance is -75.07%.

PharmAthene, Inc. (NYSEMKT:PIP) currently has a Zacks Rank #3 (Hold) PharmAthene, Inc. (NYSEMKT:PIP) shares moved down -2.08% in last trading session and was closed at $1.41, while trading in range of $1.41 – $1.49. PharmAthene, Inc. (NYSEMKT:PIP) year to date (YTD) performance is -24.19%.

On April 8, 2014 — Prosensa Holding NV (NASDAQ:RNA) announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders’ meeting, scheduled for June 17, 2014. Prosensa Holding NV (NASDAQ:RNA) weekly performance is -21.87%. On last trading day company shares ended up $-6.14. Prosensa Holding NV (NASDAQ:RNA) distance from 50-day simple moving average (SMA50) is -28.31%.